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ABSTRACT
Objective: To investigate whether simple and non-
invasive measurement of N-terminal pro-brain natriuretic
peptide (NT-proBNP) and/or C-reactive protein (CRP) can
predict perioperative major cardiovascular event (PMCE).
Design: Prospective, single-centre, cohort study.
Setting: A 1900-bed tertiary-care university hospital in
Seoul, Korea
Design and patients: The predictive power of NT-
proBNP, CRP and Revised Cardiac Risk Index (RCRI) for
the risk of PMCE (myocardial infarction, pulmonary
oedema or cardiovascular death) were evaluated from a
prospective cohort of 2054 elective major non-cardiac
surgery patients. Optimal cut-off values were derived from
receiver operating characteristic curve (ROC) analysis.
Main outcome measurement: PMCE (myocardial
infarction, pulmonary oedema or cardiovascular death)
within postoperative 30 days.
Results: PMCE developed in a total of 290 patients
(14.1%). Each increasing quartile of NT-proBNP or CRP
level was associated with a greater risk of PMCE after
adjustment for traditional clinical risk factors. The relative
risk (RR) of highest versus lowest quartile was 5.2 for NT-
proBNP (p,0.001) and 3.7 for CRP (p,0.001). Both NT-
proBNP (cut-off =301 ng/l) and CRP (cut-off =3.4 mg/l)
predicted PMCE better than RCRI (cut-off =2) by ROC
analysis (p,0.001).Moreover,thepredictivepowerofRCRI
(adjusted RR =1.5) could be improved significantly by
addition of CRP and NT-proBNP to RCRI (adjusted RR 4.6)
(p,0.001).
Conclusions: High preoperative NT-proBNP or CRP is a
strong and independent predictor of perioperative major
cardiovascular event in non-cardiac surgery. The pre-
dictive power of current clinical risk evaluation system
would be strengthened by these biomarkers.
Perioperative major cardiovascular events (PMCE)
such as acute myocardial infarction, pulmonary
oedema or primary cardiovascular death are impor-
tant causes of morbidity in patients undergoing a
major non-cardiac surgery.
1 A number of clinical
risk indices using scoring system have been
developed, but the predictive power is still insuffi-
cient.
2–5 Moreover, the results of preoperative
myocardial stress test were not consistently pre-
dictive of risk.
6–8 A simple and strongly predictive
non-invasive test is clinically warranted.
We hypothesised that the pathophysiology of
cardiovascular disease including inflammation,
myocardial ischaemia or increased ventricular
filling pressures would be important in the devel-
opment of PMCE. Then cardiovascular biomarkers
reflecting this pathophysiology would be useful for
the prediction of perioperative risk.
9 Based on
abundant clinical data, practical availability and
background pathophysiology,
10–12 we reasoned that
N-terminal pro-brain natriuretic peptide (NT-
proBNP) and C-reactive protein (CRP), representa-
tive biomarkers of haemodynamic stress and
inflammation, respectively, would be predictive of
PMCE. We investigated the predictive power of
preoperative NT-proBNP and CRP and compared it
with a well-validated clinical risk index for
perioperative cardiovascular risk in a large prospec-
tive cohort of patients undergoing elective major
non-cardiac surgery.
METHODS
Patients
We enrolled patients who were referred to con-
sulting cardiology physician for the evaluation of
preoperative cardiovascular risk if the following
criteria were fulfilled; (1) candidates for elective
major non-cardiac surgery and aged more than 21
years, and (2) at least one of cardiovascular risk
factors such as hypertension, diabetes, angina,
history of revascularisation, heart failure or stroke,
or (3) abnormal preoperative electrocardiography
with pathological Q wave or non-sinus rhythm.
Major non-cardiac surgery was defined by proce-
dures performed in the operating room requiring
general, spinal or epidural anaesthesia, after exclu-
sion of very low-risk surgeries such as dermatolo-
gical, ophthalmological, nasal or auditory
procedures.
We prospectively enrolled 2304 consecutive
patients from November 2004 to April 2008. The
following patients were excluded; surgery was not
done within 2 weeks (n=118), significant myo-
cardial ischaemia or those who required open heart
surgery (n=29). To avoid bias in the NT-proBNP
results from renal insufficiency, 103 patients with
preoperative serum creatinine >2.0 mg/dl
(>176.8 mmol/l) were also excluded.
13 The remain-
ing 2054 patients had undergone non-cardiac
surgery within 2 weeks and constituted the study
cohort (fig 1).
Data collection
Clinical perioperative cardiovascular risk was
assessed according to the Revised Cardiac Risk
Index (RCRI) modified by Lee, a well-validated and
widely used risk prediction index.
14581 4 Briefly,
RCRI calculates perioperative risk by sum of
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history of ischaemic heart disease, pulmonary oedema, cere-
brovascular disease, insulin-dependent diabetes and serum
creatinine .2.0 mg/dl, is assigned one point. The risk of major
cardiac event including myocardial infarction, pulmonary
oedema, primary cardiac arrest and complete heart block
predicted by RCRI was known to be 0.4% to 11% according
to an RCRI score of 0 to >3.
The patient’s clinical history and functional capacity were
evaluated according to the ACC/AHA guidelines on periopera-
tive cardiovascular evaluation and care for non-cardiac surgery.
8
Basic laboratory tests including electrocardiography, chest x-ray,
NT-proBNP and CRP were evaluated within 2 weeks before
surgery. Additional non-invasive tests were performed at the
physician’s discretion. Electrocardiography and serum troponin
I were evaluated at the end of the day of surgery and 24 hours
later. A chest x-ray was taken on the next day. Any abnormal
signs or symptoms suggesting pulmonary oedema or myocardial
ischaemia were followed by meticulous evaluation of periopera-
tive cardiac status with repeated cardiac serum markers and
electrocardiography. If active pulmonary oedema or ongoing
myocardial ischaemia was found, the patient was transferred to
the cardiovascular team and treated appropriately. Patients
were followed up by the consulting physician until discharge or
up to 30 days in hospital after surgery. In case of mortality, the
cause of death was decided on the consensus of the surgeon,
anaesthesiologist and cardiovascular consulting physician.
The primary endpoint was a perioperative major cardiovas-
cular event (PMCE), which was defined by any single or
combined event of secondary endpoints including myocardial
infarction, development of pulmonary oedema or primary
cardiovascular death. Myocardial infarction was defined by a
rise in postoperative troponin I above the 99th percentile of the
upper reference limit (0.78 ng/ml, Roche Diagnostics,
Switzerland). Diagnosis of pulmonary oedema required a formal
reading of chest x-ray by a radiologist consistent with the
complication. Primary cardiovascular death was defined by
sudden death that could not be explained by any other non-
cardiovascular postoperative complications. All clinical events
were collected by a research nurse and investigated by
physicians. This study protocol was approved by the institu-
tional review board of Samsung Medical Center.
Statistics
Perioperative risk predictors (RCRI, CRP and NT-proBNP) were
treated as continuous variables or ordered categorical variables.
Logarithmically transformed values of NT-proBNP and CRP
were also used to minimise distribution skewness and kurtosis.
The dose-response relation between risk predictors and clinical
outcome was investigated by the Jonckheere-Terpstra test for
trend. The predictive power of each risk predictor was also
quantitatively evaluated with relative risk per 1 SD increase of
RCRI and logarithmically transformed biomarker levels.
Receiver-operating characteristic (ROC) analysis was performed
to calculate sensitivity, specificity, area under the curve and the
optimal cut-off. The predictive power of each method was
compared using the Hanley and McNail method.
15 Relative risk
was calculated by Zhang and Yu’s method.
16 Relative risk was
also calculated for the risk predictors with values categorised by
optimal cut-off levels, or a combination of these cut-off levels in
an additive manner. Independent predictors of PMCE in
univariate analysis were included in multivariate logistic models
Figure 1 Study flowchart.
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was considered significant. SPSS version 13.0 was used mostly.
ROC curves were compared using Medcalc version 9.6.
RESULTS
Clinical characteristics
Preoperative clinical characteristics of the study population are
shown in table 1. Briefly, most patients had good functional
status without overt heart failure (functional class I or II in
94.6% and no heart failure in 97.0%). A history of angina was
found in 13.2%, including 8.0% of myocardial infarction.
Percutaneous coronary intervention (PCI) or coronary artery
bypass surgery (CABG) had been performed before non-cardiac
surgery in 14.8%. Two-dimensional echocardiography was
performed in most patients (93.6%), revealing abnormal left
ventricular wall motion in 19.9% of patients. Evidence of
myocardial ischaemia which was defined by positive non-
invasive test or significant coronary artery stenosis was found in
21.6%. A preoperative b-blocker or statin was used in 17.3% and
14.8%, respectively.
Perioperative clinical evaluation
Most patients received general anaesthesia (97.1%). Ninety-
three patients (4.5%) underwent urgent surgery within
24 hours after consultation because of altered clinical situation.
These cases were not excluded from the analysis (table 2).
Clinical outcomes
Perioperative major cardiovascular event (PMCE) had developed
in 290 (14.1%) patients. Individual patients may have had more
than one event, and all events were counted as an incidence.
There were 102 (5.0%) acute myocardial infarction, 248 (12.1%)
pulmonary oedema and 20 (1.0%) deaths, which were similar to
previous studies evaluated patients with risk of cardiovascular
disease.
1 Five patients died because of postoperative disease
progression or surgical complication (0.2%), and 15 deaths were
determined to be primary cardiovascular death (0.7%), which
included three (0.2%) acute myocardial infarction, two (0.1%)
stress-induced cardiomyopathy,
17 four (0.2%) aortic aneurysm
rupture or dissection, one (0.1%) stroke and five (0.2%) sudden
death of unknown cause (fig 1) (table 3).
Predictive power of perioperative risk predictors
We evaluated the continuous values of three risk predictors
against perioperative events. Not only increasing score of a
clinical predictor, RCRI, but also increasing quartile of
biomarker levels, NT-proBNP and CRP, was associated with a
greater risk of PMCE (p,0.001) (fig 2).
Next we investigated whether the risk predictors are related
to clinical outcomes independently each other. Each 1-SD
increase in RCRI (1 to 2) (adjusted relative risk (RR) =1.26
(95% CI 1.10 to 1.44)), log CRP (2.7 to 15.1 mg/l) (1.74 (1.55 to
1.95)) or log NT-proBNP (135 to 601 ng/l) (2.17 (1.91 to 2.45))
was associated with 1.3-fold to 2.2-fold increased rate of PMCE,
even after adjustment for other risk predictors and traditional
clinical risk factors. By subgroup analysis, CRP and NT-proBNP
were also significantly associated with all secondary endpoints,
whereas RCRI was not associated with AMI or primary
cardiovascular death. Each 1-SD increase in log CRP or log
NT-proBNP was also associated with 1.6-fold to 2.3-fold
increased risk of PMCE (table 4).
Table 1 Baseline clinical characteristics
Frequency (%) or median
(interquartile range)
Age (years) 68 (61–73)
Male gender 1247 (60.7)
Functional class III or IV 112 (5.5)
Diabetes 355 (17.3)
Diabetes treated with insulin 71 (3.5)
Hypertension 1247 (60.7)
Previous or current heart failure 62 (3.0)
Previous stroke 188 (9.3)
Angina 270 (13.2)
Previous myocardial infarction 165 (8.0)
Previous revascularisation* 304 (14.8)
Creatinine (mg/dl) 0.9 (0.7–1.1)
NT-proBNP (ng/l) 109.3 (47.0–352.8)
C-reactive protein (mg/l) 2.0 (0.7–8.0)
Electrocardiography 2054 (100)
Pathological Q waves 111 (5.4)
Atrial fibrillation 164 (8.0)
Left bundle branch block 14 (0.7)
Echocardiography 1923 (93.6)
Left ventricular ejection fraction (40% 95 (4.6)
Abnormal left ventricular wall motion 408 (19.9)
Preoperative non-invasive test{ 765 (37.2)
Overall positive result for ischaemia 188 (9.2)
Preoperative Invasive test 544 (26.5)
Significant coronary artery disease by invasive test 359 (17.5)
Any evidence of myocardial ischaemia1 444 (21.6)
Data are shown as frequency (%) or median (interquartile range) as appropriate.
*Previous revascularisation includes percutaneous coronary intervention in 222 cases
and bypass surgery in 82 cases.
{Preoperative non-invasive test includes SPECT in 577 cases, Treadmill test in 113
cases and stress echocardiography in 47 cases.
1Positive non-invasive test or coronary artery stenosis of more than 50% was defined
as any evidence of myocardial ischaemia.
Table 2 Surgical procedure and perioperative risk
Frequency (%)
Vascular surgery 531 (25.9)
Aorta 160 (7.8)
Suprainguinal vascular 98 (4.8)
Infrainguinal vascular 158 (7.7)
Carotid endarterectomy 97 (4.7)
Other vascular 18 (0.9)
Non-vascular surgery 1520 (74.4)
Thorax 85 (4.1)
Abdomen 501 (24.4)
Head and neck 178 (8.7)
Orthopaedic 439 (21.4)
Prostate 82 (4.0)
Neurosurgery 55 (2.7)
Other surgery 182 (8.9)
General anaesthesia 1994 (97.1)
Urgent surgery 93 (4.5)
RCRI (median, interquartile range) 1 (0–2)
RCRI =0 555 (27.0)
RCRI =1 846 (41.2)
RCRI =2 579 (28.2)
RCRI =3 69 (3.4)
RCRI =4 5 (0.2)
High risk surgery by RCRI* 844 (41.1)
Data are shown as frequency (%).
*Defined by intraperitoneal, intrathoracic or suprainguinal vascular surgery according
to RCRI (Revised Cardiac Risk Index modified by Lee).
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addition of biomarkers
Risk predictors categorised by optimal cut-off levels were used
to test whether the predictive power could be increased by the
combination of multiple risk factors. RCRI cut-off (>2) was
associated with 1.5-fold increased risk of PMCE after adjust-
ment for age, sex, and traditional clinical risk factors (adjusted
RR =1.50 (95% CI 1.17 to 1.91)). The risk of PMCE based on
CRP cut-off (>3.4 mg/l) and NT-proBNP cut-off (>301 ng/l)
were much higher, 2.7-fold and 3.9-fold, respectively (CRP cut-
off, 2.75 (2.16 to 3.45); NT-proBNP cut-off, 3.89 (3.15 to 4.14))
(table 4). Higher CRP and NT-proBNP values were also
associated with 2.5-fold to 5.4-fold increased risk of secondary
endpoints including AMI, pulmonary oedema, and primary
cardiovascular death (p,0.05), whereas higher RCRI was not
associated with AMI or primary cardiovascular death (table 4).
The addition of biomarkers to RCRI increased the relative risk
of RCRI for clinical events threefold. For PMCE, the adjusted
RR of RCRI increased from 1.50 (95% CI 1.17 to 1.91) to 4.55
(3.69 to 5.52) after addition of CRP and NT-proBNP. The
relative risks for secondary endpoints including AMI, pulmon-
ary oedema and primary cardiovascular death also increased
threefold to sevenfold (table 4). The increase of predictive power
of RCRI by addition of biomarkers to RCRI was again
calculated using ROC analysis. For PMCE, AUC (area under
curve) of combination of RCRI cut-off (>2) and NT-proBNP
cut-off (>301 ng/l), 0.735 (0.714 to 0.754), and AUC of
combination of RCRI cut-off and CRP cut-off (>3.4 mg/l),
0.694 (0.673 to 0.715), were significantly higher than AUC of
RCRI cut-off, 0.592 (0.570 to 0.615), (p,0.001, each). AUC of
combination of RCRI cut-off and NT-proBNP cut-off and CRP
cut-off, 0.772 (0.752 to 0.790), was even much higher than AUC
of RCRI cut-off (p,0.001) (fig 3A). The increase in AUC by
addition of biomarker cut-offs to RCRI cut-off was also evident
in all secondary endpoints including AMI, pulmonary oedema
and primary cardiovascular death (fig 3B-D).
DISCUSSION
Our study showed that the predictive power of a current
perioperative clinical risk index could be strengthened signifi-
cantly by the simple addition of the cardiovascular biomarkers,
NT-proBNP and CRP. Our findings can be summarised that the
average sensitivity of predicting perioperative major cardiovas-
cular event increased from 59% to 77% after addition of
biomarkers to clinical risk prediction system.
Predictive power of biomarker versus clinical risk index
The Revised Cardiac Risk Index modified by Lee (RCRI), which
has been shown to be superior to other perioperative risk indices
Table 3 Clinical outcome
Frequency (%)
Perioperative major cardiovascular event (PMCE) 290 (14.1)
Acute myocardial infarction 102 (5.0)
Revascularisation 26 (1.3)
Percutaneous coronary intervention 24 (1.2)
Coronary artery bypass surgery 2 (0.1)
New or aggravated heart failure 248 (12.1)
Primary cardiovascular death* 15 (0.7)
Acute myocardial infarction 3 (0.2)
Stress induced cardiomyopathy 2 (0.1)
Aortic disease 4 (0.2)
Stroke 1 (0.1)
Unknown 5 (0.2)
Death due to postoperative complication or disease progression 5 (0.2)
All death 20 (1.0)
Data are shown as frequency (%).
*Death that was not caused by postoperative complication or underlying non-
cardiovascular disease progression.
Figure 2 Clinical outcomes according to
the risk predictors. AMI, acute myocardial
infarction; CV death, primary
cardiovascular death; PMCE,
perioperative major cardiovascular event;
PE, pulmonary oedema. *p,0.001 by
Jonckheere-Terpstra test for trend.
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PMCE AMI PE CV death
RR (95% CI) p Value RR (95% CI) p Value RR (95% CI) p Value RR (95% CI) p Value
Per 1-SD increase*
RCRI 1.26 (1.10 to 1.44) 0.001 1.18 (0.88 to 1.56) 0.27 1.30 (1.13 to 1.49) ,0.001 0.53 (0.29 to 1.00) 0.05
CRP 1.74 (1.55 to 1.95) ,0.001 1.58 (1.28 to 1.93) ,0.001 1.86 (1.64 to 2.10) ,0.001 2.16 (1.32 to 3.51) 0.002
NT-proBNP 2.17 (1.91 to 2.45) ,0.001 1.55 (1.28 to 1.88) ,0.001 2.27 (1.97 to 2.62) ,0.001 2.30 (1.48 to 3.56) ,0.001
Optimal cut-off of each risk predictors{
RCRI 1.50 (1.17 to 1.91) 0.002 1.14 (0.70 to 1.86) 0.59 1.52 (1.17 to 1.96) 0.002 0.38 (0.08 to 1.71) 0.21
CRP 2.75 (2.16 to 3.45) ,0.001 2.62 (1.66 to 4.08) ,0.001 2.97 (2.28 to 3.81) ,0.001 5.38 (1.50 to 18.78) 0.010
NT-proBNP 3.89 (3.15 to 4.74) ,0.001 2.54 (1.68 to 3.79) ,0.001 4.72 (3.72 to 5.89) ,0.001 5.39 (1.86 to 15.30) 0.002
Combination of best cut-off of each predictors1
RCRI or CRP or NT-
proBNP> cut-off1
4.55 (3.69 to 5.52) ,0.001 3.24 (2.10 to 4.92) ,0.001 5.64 (4.49 to 6.96) ,0.001 7.71 (2.48 to 23.32) ,0.001
Investigate independent association of each risk predictors with clinical outcomes were shown as adjusted relative risk (RR) with 95% confidence intervals (CI), all three risk
predictors were included in the logistic regression analysis with forward conditional method. Analysis was adjusted with all significant univariate risk factors including age and sex.
*Measured in linear values, 1-SD increase from mean corresponded to 1 to 2 for RCRI, 135 ng/l to 601 ng/l for NT-proBNP, and 2.7 mg/l to 15.1 mg/l for CRP, respectively.
{Optimal cut-off values were >2 for RCRI, >301 ng/l for NT-proBNP, and >3.4 mg/l for CRP.
1Defined by at least two of three risk predictors are higher than cut-off values.
AMI, acute myocardial infarction; CV Death, primary cardiovascular death; PE, pulmonary oedema; PMCE, perioperative major cardiovascular event.
Figure 3 Receiver-operating
characteristic (ROC) analysis of
perioperative risk predictors. The
predictive power of each combination of
categorised risk predictor in an additive
manner was investigated. Risk predictors
were categorised according to the
optimal cut-off levels derived from ROC
analysis, which were 2 for RCRI, 301 ng/l
for BNP and 3.4 mg/l for CRP. Areas
under the curve (AUCs) with 95% CI are
shown below each panel. *p,0.05 by
Hanley and McNail methods. (A) ROC for
PMCE. *p,0.001 for all, except RCRI +
NT-proBNP vs RCRI + NT-proBNP + CRP
(p=0.001), and RCRI + CRP vs RCRI +
NT-proBNP (p=0.010). (B) ROC for AMI.
*p,0.001 for all, except RCRI + NT-
proBNP vs RCRI + NT-proBNP + CRP
(p=0.026), RCRI + CRP vs RCRI + NT-
proBNP + CRP (p=0.002) and RCRI +
CRP vs RCRI + NT-proBNP (p=0.590).
(C) ROC for pulmonary oedema.
*p,0.001 for all, except RCRI + CRP vs
RCRI + NT-proBNP (p=0.004) and RCRI
+ NT-proBNP vs RCRI + NT-proBNP +
CRP (p=0.001). (D) ROC for primary
cardiovascular death. *RCRI vs CRP,
p=0.021; RCRI vs RCRI + NT-proBNP,
p=0.012; RCRI vs RCRI + NT-proBNP +
CRP, p=0.002; RCRI + CRP vs RCRI +
NT-proBNP + CRP, p=0.021. AMI, acute
myocardial infarction; CV death, primary
cardiovascular death; PE, pulmonary
oedema; PMCE, perioperative major
cardiovascular event.
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2–5 The
results showed that a single cardiovascular biomarker, NT-
proBNP or CRP, is superior to clinical risk indices for the
prediction of perioperative events. In addition, both NT-proBNP
and CRP were significantly associated not only with all clinical
events but also with all subsidiary events including AMI,
pulmonary oedema and primary cardiovascular death, whereas
RCRI was not associated with primary cardiovascular death.
Furthermore, NT-proBNP and CRP were not only useful for risk
prediction but also shown to improve the predictive power of
clinical risk index. The addition of NT-proBNP and CRP to the
clinical risk index increased the adjusted relative risk threefold.
Role of NT-proBNP and CRP in the pathophysiology of
perioperative cardiovascular events
The pathophysiology of perioperative myocardial infarction has
been explained by responses to perioperative surgical stress
represented by a catecholamine surge with associated haemo-
dynamic stress, systemic inflammation and hypercoagulabil-
ity.
18 19 High NT-proBNP was associated not only with a high
risk of pulmonary oedema but also with AMI and primary
cardiovascular death in our study. This could be explained by
the release of NT-proBNP or B-natriuretic peptide (BNP) from
subclinical ischaemic or injured myocardial tissue regardless of
haemodynamic stress.
12 20 Our results strongly suggest that NT-
proBNP could be marker of myocardial ischaemia or generalised
cardiac impairment in perioperative situations as well as non-
surgical situations. The predictive power of CRP was also better
than the clinical risk index in this study. However, the high CRP
levels did not predict clinical events beyond NT-proBNP.
Previous population-based studies showed that the value of
CRP in cardiovascular risk prediction was moderate or less than
traditional risk factors.
21 22 A recently published study showed
that NT-proBNP was better than CRP for the prediction of
sudden cardiac death.
23 A relatively high CRP level in
perioperative conditions might lead to a greater contribution
of CRP to the risk prediction in our study.
Limitations
This study was performed at single centre. Only patients who
had undergone formal preoperative cardiovascular consultation
were included. However, given the strength of our results and
wide variability in the predictive power of risk indices which
highly depend on study population, it is unlikely that enrolment
of more patients would have changed the main results of our
study.
1 Long-term follow-up after discharge was not performed,
although most postoperative cardiovascular events are known
to develop in early postoperative periods.
24 25 Exclusion of
patients with renal dysfunction might have affected the
predictive power of RCRI, which includes renal function
evaluation.
13 26 Therefore, our results cannot be generalised to
patients with renal dysfunction. The presence of preoperative
infection or the use of antibiotics, which might affect the level
of CRP or the severity of perioperative systemic inflammation,
was not used as an exclusion criterion. The relation between
infection and perioperative cardiovascular disease is little known
and requires further investigation. The use of a preoperative b-
blocker or statin was less than 20% and was not associated with
clinical events in our study. The benefit of a b-blocker or statin
is currently in debate even in high-risk patients, and large
prospective trials are needed to confirm it.
62 72 8
In conclusion, our results demonstrate that high preoperative
NT-proBNP and CRP levels are strong and independent
predictors of perioperative cardiovascular events following
non-cardiac surgery. Furthermore, the predictive power of the
current clinical perioperative risk index could be strengthened
significantly by the addition of these biomarkers. Evaluation of
preoperative NT-proBNP and CRP is a practical, simple and
reasonable strategy to improve perioperative risk prediction
with minimal clinical burden and cost.
Funding: This study was supported by grants from the Samsung Medical Center
Clinical Research Development Program and the In-Sung Foundation for Medical
Research, Seoul, Korea.
Competing interests: None declared.
Provenance and peer review: Not commissioned; externally peer reviewed.
REFERENCES
1. Devereaux PJ, Goldman L, Cook DJ, et al. Perioperative cardiac events in patients
undergoing noncardiac surgery: a review of the magnitude of the problem, the
pathophysiology of the events and methods to estimate and communicate risk. CMAJ
2005;173:627–34.
2. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in
noncardiac surgical procedures. N Engl J Med 1977;297:845–50.
3. Detsky AS, Abrams HB, Forbath N, et al. Cardiac assessment for patients
undergoing noncardiac surgery. A multifactorial clinical risk index. Arch Intern Med
1986;146:2131–4.
4. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation
of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation
1999;100:1043–9.
5. Kertai MD, Boersma E, Klein J, et al. Optimizing the prediction of perioperative
mortality in vascular surgery by using a customized probability model. Arch Intern
Med 2005;165:898–904.
6. Poldermans D, Bax JJ, Schouten O, et al. Should major vascular surgery be
delayed because of preoperative cardiac testing in intermediate-risk patients
receiving beta-blocker therapy with tight heart rate control? JA mC o l lC a r d i o l
2006;48:964–9.
7. Falcone RA, Nass C, Jermyn R, et al. The value of preoperative pharmacologic
stress testing before vascular surgery using ACC/AHA guidelines: a prospective,
randomized trial. J Cardiothorac Vasc Anesth 2003;17:694–8.
8. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on
perioperative cardiovascular evaluation and care for noncardiac surgery: a report of
the American College of Cardiology/American Heart Association Task Forceo n
Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on
Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in
collaboration with the American Society of Echocardiography, American Society of
Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular
Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society
for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll
Cardiol 2007;50:e159–241.
9. Kistorp C, Raymond I, Pedersen F, et al. N-terminal pro-brain natriuretic peptide, C-
reactive protein, and urinary albumin levels as predictors of mortality and
cardiovascular events in older adults. JAMA 2005;293:1609–16.
10. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to
improve the prediction of death from cardiovascular causes. N Engl J Med
2008;358:2107–16.
11. Timpson NJ, Lawlor DA, Harbord RM, et al. C-reactive protein and its role in
metabolic syndrome: mendelian randomisation study. Lancet 2005;366:1954–9.
12. Morrow DA, de Lemos JA, Blazing MA, et al. Prognostic value of serial B-type
natriuretic peptide testing during follow-up of patients with unstable coronary artery
disease. JAMA 2005;294:2866–71.
13. Goei D, Schouten O, Boersma E, et al. Influence of renal function on the usefulness
of N-terminal pro-B-type natriuretic peptide as a prognostic cardiac risk marker in
patients undergoing noncardiac vascular surgery. Am J Cardiol 2008;101:122–6.
14. Laine C, Williams SV, Wilson JF. In the clinic. Preoperative evaluation. Ann Intern
Med 2009;151:ITC1–16.
15. Stephan C, Wesseling S, Schink T, et al. Comparison of eight computer programs for
receiver-operating characteristic analysis. Clin Chem 2003;49:433–9.
16. Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in
cohort studies of common outcomes. JAMA 1998;280:1690–1.
17. Hahn JY, Gwon HC, Park SW, et al. The clinical features of transient left ventricular
nonapical ballooning syndrome: comparison with apical ballooning syndrome. Am
Heart J 2007;154:1166–73.
18. Poldermans D, Hoeks SE, Feringa HH. Pre-operative risk assessment and risk
reduction before surgery. J Am Coll Cardiol 2008;51:1913–24.
19. Schouten O, Bax JJ, Poldermans D. Preoperative cardiac risk assessment in
vascular surgery patients: seeing beyond the perioperative period. Eur Heart J
2008;29:283–4.
20. Sabatine MS, Morrow DA, de Lemos JA, et al. Acute changes in circulating
natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol
2004;44:1988–95.
Biomarkers and heart disease
Heart 2010;96:56–62. doi:10.1136/hrt.2009.181388 6121. Van der Meer IM, de Maat MP, Kiliaan AJ, et al. The value of C-reactive protein in
cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 2003;163:1323–8.
22. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone
replacement therapy, and incident coronary heart disease: prospective analysis from
the Women’s Health Initiative observational study. JAMA 2002;288:980–7.
23. Korngold EC, Januzzi JL Jr, Gantzer ML, et al. Amino-terminal pro-B-type natriuretic
peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death
among women. Circulation 2009;119:2868–76.
24. McFalls EO, Ward HB, Moritz TE, et al. Predictors and outcomes of a perioperative
myocardial infarction following elective vascular surgery in patients with documented
coronary artery disease: results of the CARP trial. Eur Heart J 2008;29:394–401.
25. Owens CD, Ridker PM, Belkin M, et al. Elevated C-reactive protein levels are
associated with postoperative events in patients undergoing lower extremity vein
bypass surgery. J Vasc Surg 2007;45:2–9; discussion 9.
26. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal
function in the diagnosis of heart failure: an analysis from the Breathing Not Properly
Multinational Study. Am J Kidney Dis 2003;41:571–9.
27. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol
succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised
controlled trial. Lancet 2008;371:1839–47.
28. Bangalore S, Wetterslev J, Pranesh S, et al. Perioperative beta blockers in patients
having non-cardiac surgery: a meta-analysis. Lancet 2008;372:1962–76.
Biomarkers and heart disease
62 Heart 2010;96:56–62. doi:10.1136/hrt.2009.181388